Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .
Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease.
BACKGROUND To evaluate the impact of the extent of coronary disease ( single- or multivessel ) and of fluvastatin treatment on the incidence of long-term cardiac atherosclerotic complications in the Lescol Intervention Prevention Study ( LIPS ) . METHODS A total of 1063 patients with single-vessel disease and 614 patients with multivessel disease were r and omized to receive fluvastatin ( 40 mg bid ) or placebo for at least 3 years following a first successful percutaneous coronary intervention . The incidence of cardiac atherosclerotic events ( cardiac death , non-fatal myocardial infa rct ion , and coronary re- interventions not related to restenosis ) was evaluated . RESULTS Patients with multivessel disease tended to be older and presented a higher prevalence of associated risk factors and cardiovascular antecedents . The presence of multivessel disease markedly increased the risk of cardiac atherosclerotic events compared with single-vessel disease among patients allocated to placebo ( RR 1.67 [ 95 % CI : 1.24 - 2.25 ] ; p<0.001 ) . In patients treated with fluvastatin , however , no significant differences in long-term outcomes were observed between patients with multivessel disease and patients single-vessel disease ( RR 1.28 [ 95 % CI : 0.90 - 1.81 ] ; p=0.2 ) . CONCLUSIONS Multivessel coronary disease impaired the 4-year outcomes after percutaneous intervention . However , the hazardous effect of multivessel disease was significantly reduced by long-term fluvastatin treatment
Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .